Merit Medical Systems, Inc.

NasdaqGS:MMSI 주식 리포트

시가총액: US$5.3b

Merit Medical Systems 향후 성장

Future 기준 점검 1/6

Merit Medical Systems (는) 각각 연간 12.6% 및 5.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 11.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 13.6% 로 예상됩니다.

핵심 정보

12.6%

이익 성장률

11.25%

EPS 성장률

Medical Equipment 이익 성장16.9%
매출 성장률5.9%
향후 자기자본이익률13.58%
애널리스트 커버리지

Good

마지막 업데이트31 Jul 2026

최근 향후 성장 업데이트

Recent updates

내러티브 업데이트 • Jul 31

MMSI: Strong Q2 Execution And 2026 Guidance Will Test Earnings Power

Merit Medical Systems' analyst fair value estimate has increased from $74.00 to $83.00, in line with higher Street price targets after analysts highlighted a strong Q2 report, a rebound in organic growth, raised 2026 guidance and expectations for improved margins and earnings power. Analyst Commentary The recent research coverage on Merit Medical Systems centers on a stronger Q2 print, higher 2026 guidance and a series of upward price target revisions.
내러티브 업데이트 • Jul 03

MMSI: Lower P/E Assumptions Will Set Up Future Repricing Potential

The analyst price target for Merit Medical Systems has been reduced from about $118 to $110 as analysts incorporate a slightly lower assumed future P/E multiple, while maintaining modestly higher revenue growth and profit margin assumptions. Analyst Commentary Recent Street research on Merit Medical Systems has centered on lower price targets, but many reports still highlight constructive views on the company’s execution and long term opportunity set.
내러티브 업데이트 • Jun 19

MMSI: Discount Rate Reset And 2026 Guidance Will Support Share Price

Analysts have trimmed their price targets on Merit Medical Systems by between $2 and $20, with the updated fair value estimate holding near $89.55 as they adjust assumptions around discount rates and valuation multiples while keeping revenue growth and profit margin expectations broadly unchanged. Analyst Commentary Recent Street research around Merit Medical Systems shows a cluster of reduced price targets, but the commentary behind those changes is more mixed.
내러티브 업데이트 • Jun 04

MMSI: Margin Strength And 2026 Guidance Reset Will Drive Future Upside

Merit Medical Systems' analyst price target has been reset lower by about $8.82 per share. This change reflects analysts' updated assumptions for slightly softer revenue growth, a modestly lower discount rate, stronger profit margins, and a reduced future P/E multiple.
새로운 내러티브 • May 16

Oncology And Endoscopy Platforms Will Reshape Long Term Earnings Power

Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?
Seeking Alpha • May 02

Merit Medical Systems: Creating More Growth Engines (Rating Upgrade)

Summary Merit Medical Systems trades at 17-18x earnings with solid fundamentals, moderate leverage, and reasonable valuation, supporting an upbeat outlook. Q1 organic growth was on the lower end, but full-year guidance was maintained and even slightly raised for sales, reflecting recent M&A contributions. Growth engines include the View Point Medical acquisition and WRAPSODY, both expected to accelerate revenue and margin expansion into 2026. Despite softer organic growth and CEO transition, Merit's business remains resilient, with potential for re-rating as growth drivers materialize. Read the full article on Seeking Alpha
새로운 내러티브 • May 01

Tariffs And OEM Volatility Will Pressure Margins Yet Long Term Procedure Demand Will Support Progress

Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?
내러티브 업데이트 • Apr 24

MMSI: 2026 Guidance Execution And Margin Resilience Will Drive Future Upside

Analysts have nudged their price targets on Merit Medical slightly lower, with the updated fair value estimate moving from about $101.18 to $98.36 as they factor in modestly softer profit margin assumptions and a somewhat higher future P/E multiple, alongside recent target cuts and a downgrade tied to 2026 guidance uncertainty. Analyst Commentary Recent research on Merit Medical Systems highlights a mix of confidence in the business model and caution around execution against medium term targets, especially the 2026 outlook.
내러티브 업데이트 • Apr 08

MMSI: 2026 Margin Outlook And Guidance Will Drive Upside Potential

Analysts have trimmed the blended fair value estimate for Merit Medical Systems to about $101 from roughly $104, reflecting a lower projected price target that incorporates higher discount rates, slightly softer revenue growth assumptions, and a more moderate future P/E multiple, even as margin expectations improve. Analyst Commentary Recent Street research on Merit Medical Systems presents a mixed picture, with some analysts trimming targets or ratings on guidance uncertainty, while others still see room for valuation support based on execution and margins.
분석 기사 • Dec 31

We Like These Underlying Return On Capital Trends At Merit Medical Systems (NASDAQ:MMSI)

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Seeking Alpha • Mar 16

Merit Medical: A Success Story That Keeps Getting Better

Summary Merit Medical continues to outperform, with the share price supported by on-target financial results, incremental M&A, and positive clinical data. The company's Wrapsody stent graft showed almost best-case clinical efficacy, positioning it to capture significant market share in dialysis graft occlusion procedures. Recent acquisitions, including EsophyX Z+ and Cook Medical’s lead management portfolio, enhance Merit’s product portfolio and offer longer-term synergies. CEO succession remains a concern, but could also prompt a bid for the company. Despite not being "super cheap", Merit’s strong execution, revenue growth, and margin leverage justify a positive rating, with potential for further valuation uplift. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

Merit Medical Systems: Solid Execution, Stretched Valuations

Summary Merit Medical Systems' stock is up 40% from last spring's lows, driven by strong Q3 results and positive analyst sentiment. The stock's rally has stalled recently. The company has also made a small acquisition in September and garnered a key FDA approval to close out 2024 on a high note. More upside ahead, or will the shares experience further profit-taking?  An analysis of Merit Medical Systems follows in the paragraphs below. Read the full article on Seeking Alpha

이익 및 매출 성장 예측

NasdaqGS:MMSI - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/20281,8432162903717
12/31/20271,73619927433211
12/31/20261,63616923731911
6/30/20261,579146200283N/A
3/31/20261,542139217297N/A
12/31/20251,516128213297N/A
9/30/20251,477118204268N/A
6/30/20251,433119190240N/A
3/31/20251,388122178225N/A
12/31/20241,357120183221N/A
9/30/20241,326120173214N/A
6/30/20241,301117177218N/A
3/31/20241,283102131167N/A
12/31/20231,25794108145N/A
9/30/20231,22610068111N/A
6/30/20231,198904595N/A
3/31/20231,1738565117N/A
12/31/20221,1517566114N/A
9/30/20221,1366289132N/A
6/30/20221,1165887122N/A
3/31/20221,1014890124N/A
12/31/20211,07548116147N/A
9/30/20211,05443105138N/A
6/30/20211,03128133168N/A
3/31/20219694131172N/A
12/31/2020964-10116165N/A
9/30/2020964-2996155N/A
6/30/2020963-3044115N/A
3/31/20201,000-4N/A93N/A
12/31/20199955N/A78N/A
9/30/201997019N/A75N/A
6/30/201994939N/A87N/A
3/31/201991843N/A92N/A
12/31/201888342N/A87N/A
9/30/201884040N/A82N/A
6/30/201879819N/A63N/A
3/31/201876018N/A55N/A
12/31/201772828N/A63N/A
9/30/201769528N/A61N/A
6/30/201767233N/A63N/A
3/31/201763731N/A57N/A
12/31/201660420N/A54N/A
9/30/201658019N/A49N/A
6/30/201655923N/A55N/A
3/31/201654623N/A62N/A
12/31/201554224N/A69N/A
9/30/201553726N/A79N/A

애널리스트 향후 성장 전망

수입 대 저축률: MMSI 의 연간 예상 수익 증가율(12.6%)이 saving rate(3.7%)보다 높습니다.

수익 vs 시장: MMSI 의 연간 수익(12.6%)이 US 시장(16.8%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: MMSI 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: MMSI 의 수익(연간 5.9%)이 US 시장(연간 12.9%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: MMSI 의 수익(연간 5.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: MMSI의 자본 수익률은 3년 후 13.6%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/08/10 13:11
종가2026/08/10 00:00
수익2026/06/30
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Merit Medical Systems, Inc.는 22명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
null nullBaird
David RescottBaird
Michael PetuskyBarrington Research Associates, Inc.